Jennifer N Fishe1,2, Guillaume Labilloy2, Rebecca Higley1, Deirdre Casey3, Amber Ginn4, Brett Baskovich4, Kathryn V Blake5. 1. Department of Emergency Medicine, Division of Research, University of Florida College of Medicine - Jacksonville. 2. Center for Data Solutions, University of Florida College of Medicine - Jacksonville. 3. University of Florida Health Jacksonville, Jacksonville. 4. Department of Pathology, University of Florida College of Medicine - Jacksonville. 5. Nemours Center for Pharmacogenomics and Translational Research, Jacksonville, Florida, USA.
Abstract
OBJECTIVE: Inhaled bronchodilators are the first-line treatment for asthma exacerbations, but individual bronchodilator response (BDR) varies by race and ethnicity. Studies have examined BDR's genetic underpinnings, but many did not include children or were not conducted during an asthma exacerbation. This pilot study tested single-nucleotide polymorphisms' (SNPs') association with pediatric African American BDR during an acute asthma exacerbation. METHODS: This was a study of pediatric asthma patients in the age group 2-18 years treated in the emergency department for an asthma exacerbation. We measured BDR before and after inhaled bronchodilator treatments using both the Pediatric Asthma Severity Score (PASS) and asthma severity score. We collected genomic DNA and examined whether 21 candidate SNPs from a review of the literature were associated with BDR using crude odds ratios (OR) and adjusted analysis. RESULTS: The final sample population was 53 children, with an average age of 7.2 years. The average initial PASS score (scale of ascending severity from 0 to 6) was 2.5. After adjusting for BMI, age category, gender and smoke exposure, rs912142 was associated with decreased odds of having low BDR (OR, 0.20; 95% confidence interval (CI), 0.02-0.92), and rs7081864 and rs7903366 were associated with decreased odds of having high BDR (OR, 0.097; 95% CI, 0.009-0.62). CONCLUSIONS: We found three SNPs significantly associated with pediatric African American BDR that provide information regarding a child's potential response to emergency asthma exacerbation treatment. Once validated in larger studies, such information could guide pharmacogenomic evidence-based emergency asthma treatment to improve patient outcomes.
OBJECTIVE: Inhaled bronchodilators are the first-line treatment for asthma exacerbations, but individual bronchodilator response (BDR) varies by race and ethnicity. Studies have examined BDR's genetic underpinnings, but many did not include children or were not conducted during an asthma exacerbation. This pilot study tested single-nucleotide polymorphisms' (SNPs') association with pediatric African American BDR during an acute asthma exacerbation. METHODS: This was a study of pediatric asthma patients in the age group 2-18 years treated in the emergency department for an asthma exacerbation. We measured BDR before and after inhaled bronchodilator treatments using both the Pediatric Asthma Severity Score (PASS) and asthma severity score. We collected genomic DNA and examined whether 21 candidate SNPs from a review of the literature were associated with BDR using crude odds ratios (OR) and adjusted analysis. RESULTS: The final sample population was 53 children, with an average age of 7.2 years. The average initial PASS score (scale of ascending severity from 0 to 6) was 2.5. After adjusting for BMI, age category, gender and smoke exposure, rs912142 was associated with decreased odds of having low BDR (OR, 0.20; 95% confidence interval (CI), 0.02-0.92), and rs7081864 and rs7903366 were associated with decreased odds of having high BDR (OR, 0.097; 95% CI, 0.009-0.62). CONCLUSIONS: We found three SNPs significantly associated with pediatric African American BDR that provide information regarding a child's potential response to emergency asthma exacerbation treatment. Once validated in larger studies, such information could guide pharmacogenomic evidence-based emergency asthma treatment to improve patient outcomes.
Authors: Angel C Y Mak; Marquitta J White; Walter L Eckalbar; Zachary A Szpiech; Sam S Oh; Maria Pino-Yanes; Donglei Hu; Pagé Goddard; Scott Huntsman; Joshua Galanter; Ann Chen Wu; Blanca E Himes; Soren Germer; Julia M Vogel; Karen L Bunting; Celeste Eng; Sandra Salazar; Kevin L Keys; Jennifer Liberto; Thomas J Nuckton; Thomas A Nguyen; Dara G Torgerson; Pui-Yan Kwok; Albert M Levin; Juan C Celedón; Erick Forno; Hakon Hakonarson; Patrick M Sleiman; Amber Dahlin; Kelan G Tantisira; Scott T Weiss; Denise Serebrisky; Emerita Brigino-Buenaventura; Harold J Farber; Kelley Meade; Michael A Lenoir; Pedro C Avila; Saunak Sen; Shannon M Thyne; William Rodriguez-Cintron; Cheryl A Winkler; Andrés Moreno-Estrada; Karla Sandoval; Jose R Rodriguez-Santana; Rajesh Kumar; L Keoki Williams; Nadav Ahituv; Elad Ziv; Max A Seibold; Robert B Darnell; Noah Zaitlen; Ryan D Hernandez; Esteban G Burchard Journal: Am J Respir Crit Care Med Date: 2018-06-15 Impact factor: 30.528
Authors: B Padhukasahasram; J J Yang; A M Levin; M Yang; E G Burchard; R Kumar; P-Y Kwok; M A Seibold; D E Lanfear; L K Williams Journal: Pharmacogenomics J Date: 2014-01-14 Impact factor: 3.550
Authors: Adaeze C Ayuk; Samuel N Uwaezuoke; Chizalu I Ndukwu; Ikenna K Ndu; Kenechukwu K Iloh; Chinyere V Okoli Journal: Clin Med Insights Pediatr Date: 2017-07-19
Authors: Tomoyuki Mizuno; Min Dong; Zachary L Taylor; Laura B Ramsey; Alexander A Vinks Journal: Br J Clin Pharmacol Date: 2020-07-08 Impact factor: 4.335